CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics development company specializing in gene editing platform technology. It is a spin-out of ChristianaCare and the Gene Editing Institute, aiming to develop innovative treatments for solid tumors using CRISPR/Cas biomolecular tools to disable specific genes like NRF2, thereby altering the tumor microenvironment and overcoming drug resistance. The company leverages a proprietary in vivo gene editing platform and lipid nanoparticle delivery systems to minimize off-target effects and broad applicability across multiple squamous cell carcinomas.
Industries
Nr. of Employees
small (1-50)
CorriXR Therapeutics
Products
Preclinical NRF2-targeting in vivo gene-editing therapeutic (lead program)
A preclinical therapeutic approach using an in vivo gene-editing agent delivered by lipid nanoparticles via intratumoral administration to disable NRF2 in tumor cells and sensitize squamous cell carcinomas to standard treatments.
Preclinical NRF2-targeting in vivo gene-editing therapeutic (lead program)
A preclinical therapeutic approach using an in vivo gene-editing agent delivered by lipid nanoparticles via intratumoral administration to disable NRF2 in tumor cells and sensitize squamous cell carcinomas to standard treatments.
Services
Translational research partnerships
Collaborative programs with academic and clinical partners to advance gene-editing therapeutics from bench to bedside, including access to clinicians and patient populations for translational studies.
Preclinical model development and in vivo study execution
Design and execution of in vitro assays and in vivo studies using cell lines, PDX/PDC mouse models, and partner large-animal facilities to validate gene-editing therapeutics.
Molecular characterization and sequencing services
Application of next-generation sequencing workflows to characterize gene edits, assess on/off-target effects, and support preclinical validation.
Translational research partnerships
Collaborative programs with academic and clinical partners to advance gene-editing therapeutics from bench to bedside, including access to clinicians and patient populations for translational studies.
Preclinical model development and in vivo study execution
Design and execution of in vitro assays and in vivo studies using cell lines, PDX/PDC mouse models, and partner large-animal facilities to validate gene-editing therapeutics.
Molecular characterization and sequencing services
Application of next-generation sequencing workflows to characterize gene edits, assess on/off-target effects, and support preclinical validation.
Expertise Areas
- In vivo gene editing therapeutics
- Oncology-focused translational development
- Preclinical model development (PDX/PDC)
- Nucleic acid delivery formulation (LNP)
Key Technologies
- CRISPR/Cas gene editing
- Lipid nanoparticle delivery
- Intratumoral injection delivery
- Patient-derived xenograft (PDX) models